FIVE THINGS TO KNOW ABOUT ... Psoriasis

被引：1
|
作者：
Freiman, Anatoli [1 ]
Barankin, Benjamin [1 ]
机构：
[1] Toronto Psoriasis Ctr, Toronto, ON, Canada
来源：
CANADIAN MEDICAL ASSOCIATION JOURNAL | 2013年 / 185卷 / 03期
关键词：
PLAQUE PSORIASIS; MODERATE;
D O I：
10.1503/cmaj.090631
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E174 / E174
页数：1
相关论文
共 13 条
  • [1] What anesthesiologists should know about paracetamol (acetaminophen)
    Mattia, C.
    Coluzzi, F.
    MINERVA ANESTESIOLOGICA, 2009, 75 (11) : 644 - 653
  • [2] What Do We Know About Adherence to Oral Appliances?
    Sutherland, Kate
    Dalci, Oyku
    Cistulli, Peter A.
    SLEEP MEDICINE CLINICS, 2021, 16 (01) : 145 - 154
  • [3] The comparative burden of chronic spontaneous urticaria, atopic dermatitis and psoriasis in five European countries
    Balp, Maria-Magdalena
    Krupsky, Kathryn
    Gupta, Shaloo
    Balkaran, Bridget L.
    Kohli, Ravneet K.
    Lienhard, Clementine
    Loh, Jaclyn
    Rodriguez Barrios, Jose M.
    Patil, Dhaval
    Tetart, Florence
    El-Shanawany, Tariq
    Reed, John
    JEADV CLINICAL PRACTICE, 2024, 3 (02): : 508 - 520
  • [4] What do we know about carbon monoxide poisoning and cardiac compromise?
    Cardiga, Rosa
    Proenca, Margarida
    Carvalho, Carolina
    Costa, Luis
    Botella, Arturo
    Marques, Filipa
    Paulino, Carolina
    Carvalho, Antonio
    Fonseca, Candida
    REVISTA PORTUGUESA DE CARDIOLOGIA, 2015, 34 (09) : 557e1 - 557e5
  • [5] Efficacy of Systemic Biologic Drugs in Pediatric Psoriasis: Evidence From Five Selected Randomized Clinical Trials
    Di Lernia, Vito
    Macca, Laura
    Peterle, Lucia
    Ingrasciotta, Ylenia
    Trifiro, Gianluca
    Guarneri, Claudio
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [6] Apremilast Survival and Reasons for Discontinuation in Psoriasis: Five-Year Experience From a Greek Tertiary Care Centre
    Sotiriou, Elena
    Tsentemeidou, Aikaterini
    Sideris, Nikolaos
    Lallas, Aimilios
    Kougkas, Nikolaos
    Ioannides, Dimitrios
    Vakirlis, Efstratios
    DERMATOLOGY PRACTICAL & CONCEPTUAL, 2022, 12 (02):
  • [7] New generation biologics for the treatment of psoriasis and psoriatic arthritis. State of the art and considerations about the risk of infection
    Ceccarelli, Manuela
    Rullo, Emmanuele Venanzi
    Berretta, Massimiliano
    Cacopardo, Bruno
    Pellicano, Giovanni Francesco
    Nunnari, Giuseppe
    Guarneri, Claudio
    DERMATOLOGIC THERAPY, 2021, 34 (01)
  • [8] Sustained High Efficacy and Favorable Safety Over Five Years in Patients With Burdensome Psoriasis (UNCOVER-1/UNCOVER-2)
    Papp, Kim A.
    Gerdes, Sascha
    Leonardi, Craig L.
    Elmaraghy, Hany
    See, Kyoungah
    McKean-Matthews, Missy
    Konicek, Bruce W.
    Crane, Heidi M.
    Eastman, William
    JOURNAL OF DRUGS IN DERMATOLOGY, 2021, 20 (08) : 880 - 887
  • [9] Five-year Maintenance of Clinical Response and Consistent Safety Profile for Guselkumab in Asian patients with Psoriasis from VOYAGE 1 and VOYAGE 2
    Kim, Byung Soo
    Jo, Seong Jin
    Youn, Sangwoong
    Reich, Kristian
    Saadoun, Carine
    Chang, Chia-Ling
    Yang, Ya-Wen
    Huang, Yu-Huei
    Tsai, Tsen-Fang
    DERMATOLOGY AND THERAPY, 2023, 13 (11) : 2721 - 2737
  • [10] Real-world outcomes in 2646 psoriasis patients: one in five has PASI ≥10 and/or DLQI ≥10 under ongoing systemic therapy
    Norlin, J. M.
    Calara, P. S.
    Persson, U.
    Schmitt-Egenolf, M.
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2017, 28 (06) : 500 - 504
12